Type 2 diabetes patients have a high risk of developing NAFLD. This was confirmed during previous research, a high prevalence of NAFLD among type 2 diabetes mellitus patients was found. The investigators want to determine the characteristics of this population.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
VCTEM (KPa) measure
Timeframe: up to year four
CAPTM (dB/m) measure
Timeframe: up to year four
Liver Ultrasound
Timeframe: up to year four
Liver biopsy
Timeframe: up to year four
Aspartate transaminase (AST)
Timeframe: up to year four
Alanine transaminase (ALT)
Timeframe: up to year four
Gamma glutamyltransferase (GGT)
Timeframe: up to year four
Lactate dehydrogenase (LDH)
Timeframe: up to year four
total protein
Timeframe: up to year four
Albumin
Timeframe: up to year four
Ferritin
Timeframe: up to year four
bilirubin total
Timeframe: up to year four
Exclusion of other liver diseases
Timeframe: up to year four
Weight
Timeframe: up to year four
Height
Timeframe: up to year four
BMI (Body Mass Index)
Timeframe: up to year four
waist circumference
Timeframe: up to year four
Wellbeing - BAECKE
Timeframe: up to year four
Wellbeing - GAD-7
Timeframe: up to year four
Wellbeing - PHQ-9
Timeframe: up to year four
Wellbeing - WPAI-SHP
Timeframe: up to year four
Wellbeing - SF-36
Timeframe: up to year four
Diagnosis Diabetes
Timeframe: up to year four
Diabetes complications
Timeframe: up to year four